Cost-effectiveness analysis of local treatment in oligometastatic disease
BackgroundIn certain malignancies, patients with oligometastatic disease benefit from radical ablative or surgical treatment. The SABR-COMET trial demonstrated a survival benefit for oligometastatic patients randomized to local stereotactic ablative radiation (SABR) compared to patients receiving st...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 June 2021
|
| In: |
Frontiers in oncology
Year: 2021, Jahrgang: 11, Pages: 1-8 |
| ISSN: | 2234-943X |
| DOI: | 10.3389/fonc.2021.667993 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3389/fonc.2021.667993 Verlag, lizenzpflichtig, Volltext: https://www.frontiersin.org/article/10.3389/fonc.2021.667993 
|
| Verfasserangaben: | Dirk Mehrens, Marcus Unterrainer, Stefanie Corradini, Maximilian Niyazi, Farkhad Manapov, C. Benedikt Westphalen, Matthias F. Froelich, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Johannes Rübenthaler and Wolfgang G. Kunz |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1773385089 | ||
| 003 | DE-627 | ||
| 005 | 20230428030157.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211012s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2021.667993 |2 doi | |
| 035 | |a (DE-627)1773385089 | ||
| 035 | |a (DE-599)KXP1773385089 | ||
| 035 | |a (OCoLC)1341421921 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mehrens, Dirk |d 1988- |e VerfasserIn |0 (DE-588)119119809X |0 (DE-627)1669600335 |4 aut | |
| 245 | 1 | 0 | |a Cost-effectiveness analysis of local treatment in oligometastatic disease |c Dirk Mehrens, Marcus Unterrainer, Stefanie Corradini, Maximilian Niyazi, Farkhad Manapov, C. Benedikt Westphalen, Matthias F. Froelich, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Johannes Rübenthaler and Wolfgang G. Kunz |
| 264 | 1 | |c 15 June 2021 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a BackgroundIn certain malignancies, patients with oligometastatic disease benefit from radical ablative or surgical treatment. The SABR-COMET trial demonstrated a survival benefit for oligometastatic patients randomized to local stereotactic ablative radiation (SABR) compared to patients receiving standard care (SC) alone. Our aim was to determine the cost-effectiveness of SABR.Materials and MethodsA decision model based on partitioned survival simulations estimated costs and quality-adjusted life years (QALY) associated with both strategies in a United States setting from a health care perspective. Analyses were performed over the trial duration of six years as well as a long-term horizon of 16 years. Model input parameters were based on the SABR-COMET trial data as well as best available and most recent data provided in the published literature. An annual discount of 3% for costs was implemented in the analysis. All costs were adjusted to 2019 US Dollars according to the United States Consumer Price Index. SABR costs were reported with an average of $11,700 per treatment. Deterministic and probabilistic sensitivity analyses were performed. Incremental costs, effectiveness, and cost-effectiveness ratios (ICER) were calculated. The willingness-to-pay (WTP) threshold was set to $100,000/QALY.ResultsBased on increased overall and progression-free survival, the SABR group showed 0.78 incremental QALYs over the trial duration and 1.34 incremental QALYs over the long-term analysis. Treatment with SABR led to a marginal increase in costs compared to SC alone (SABR: $304,656; SC: $303,523 for 6 years; ICER $1,446/QALY and SABR: $402,888; SC: $350,708 for long-term analysis; ICER $38,874/QALY). Therapy with SABR remained cost-effective until treatment costs of $88,969 over the trial duration (i.e. 7.6 times the average cost). Sensitivity analysis identified a strong model impact for ongoing annual costs of oligo- and polymetastatic disease states.ConclusionOur analysis suggests that local treatment with SABR adds QALYs for patients with certain oligometastatic cancers and represents an intermediate- and long-term cost-effective treatment strategy. | ||
| 700 | 1 | |a Unterrainer, Marcus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Corradini, Stefanie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Niyazi, Maximilian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Manapov, Farkhad |e VerfasserIn |4 aut | |
| 700 | 1 | |a Westphalen, C. Benedikt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Froelich, Matthias F. |d 1991- |e VerfasserIn |0 (DE-588)1170833756 |0 (DE-627)1040131557 |0 (DE-576)512678359 |4 aut | |
| 700 | 1 | |a Wildgruber, Moritz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seidensticker, Max |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ricke, Jens |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rübenthaler, Johannes |d 1987- |e VerfasserIn |0 (DE-588)1064849903 |0 (DE-627)815222009 |0 (DE-576)424189941 |4 aut | |
| 700 | 1 | |a Kunz, Wolfgang Gerhard |d 1987- |e VerfasserIn |0 (DE-588)1147994978 |0 (DE-627)1007483601 |0 (DE-576)496130781 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d Lausanne : Frontiers Media, 2011 |g 11(2021), Artikel-ID 667993, Seite 1-8 |h Online-Ressource |w (DE-627)684965518 |w (DE-600)2649216-7 |w (DE-576)35841184X |x 2234-943X |7 nnas |a Cost-effectiveness analysis of local treatment in oligometastatic disease |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g elocationid:667993 |g pages:1-8 |g extent:8 |a Cost-effectiveness analysis of local treatment in oligometastatic disease |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fonc.2021.667993 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/article/10.3389/fonc.2021.667993 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211012 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1170833756 |a Froelich, Matthias F. |m 1170833756:Froelich, Matthias F. |d 60000 |d 62900 |e 60000PF1170833756 |e 62900PF1170833756 |k 0/60000/ |k 1/60000/62900/ |p 7 | ||
| 999 | |a KXP-PPN1773385089 |e 3988650129 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Cost-effectiveness analysis of local treatment in oligometastatic disease","title_sort":"Cost-effectiveness analysis of local treatment in oligometastatic disease"}],"id":{"eki":["1773385089"],"doi":["10.3389/fonc.2021.667993"]},"recId":"1773385089","language":["eng"],"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"15 June 2021"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"family":"Mehrens","roleDisplay":"VerfasserIn","display":"Mehrens, Dirk","role":"aut","given":"Dirk"},{"display":"Unterrainer, Marcus","role":"aut","given":"Marcus","roleDisplay":"VerfasserIn","family":"Unterrainer"},{"roleDisplay":"VerfasserIn","family":"Corradini","given":"Stefanie","role":"aut","display":"Corradini, Stefanie"},{"given":"Maximilian","display":"Niyazi, Maximilian","role":"aut","family":"Niyazi","roleDisplay":"VerfasserIn"},{"display":"Manapov, Farkhad","role":"aut","given":"Farkhad","roleDisplay":"VerfasserIn","family":"Manapov"},{"display":"Westphalen, C. Benedikt","role":"aut","given":"C. Benedikt","roleDisplay":"VerfasserIn","family":"Westphalen"},{"family":"Froelich","roleDisplay":"VerfasserIn","role":"aut","display":"Froelich, Matthias F.","given":"Matthias F."},{"family":"Wildgruber","roleDisplay":"VerfasserIn","display":"Wildgruber, Moritz","role":"aut","given":"Moritz"},{"given":"Max","display":"Seidensticker, Max","role":"aut","roleDisplay":"VerfasserIn","family":"Seidensticker"},{"roleDisplay":"VerfasserIn","family":"Ricke","role":"aut","display":"Ricke, Jens","given":"Jens"},{"role":"aut","display":"Rübenthaler, Johannes","given":"Johannes","roleDisplay":"VerfasserIn","family":"Rübenthaler"},{"roleDisplay":"VerfasserIn","family":"Kunz","given":"Wolfgang Gerhard","role":"aut","display":"Kunz, Wolfgang Gerhard"}],"name":{"displayForm":["Dirk Mehrens, Marcus Unterrainer, Stefanie Corradini, Maximilian Niyazi, Farkhad Manapov, C. Benedikt Westphalen, Matthias F. Froelich, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Johannes Rübenthaler and Wolfgang G. Kunz"]},"physDesc":[{"extent":"8 S."}],"relHost":[{"disp":"Cost-effectiveness analysis of local treatment in oligometastatic diseaseFrontiers in oncology","note":["Gesehen am 07.11.13"],"id":{"issn":["2234-943X"],"eki":["684965518"],"zdb":["2649216-7"]},"title":[{"title":"Frontiers in oncology","title_sort":"Frontiers in oncology"}],"part":{"pages":"1-8","year":"2021","extent":"8","volume":"11","text":"11(2021), Artikel-ID 667993, Seite 1-8"},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"origin":[{"publisher":"Frontiers Media","dateIssuedKey":"2011","publisherPlace":"Lausanne","dateIssuedDisp":"2011-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["2011 -"],"recId":"684965518"}]} | ||
| SRT | |a MEHRENSDIRCOSTEFFECT1520 | ||